title: HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density.
abstract: OBJECTIVE
  HMG CoA reductase inhibitors reduce cellular availability of mevalonate, a precursor in cholesterol synthesis. Since the cholesterol content of cell membranes is an important determinant of Na(+)-K(+) pump function we speculated that treatment with HMG CoA reductase inhibitors affects Na(+)-K(+) pump activity.
  
  
  METHODS
  We treated rabbits and rats for 2 weeks with the HMG CoA reductase inhibitor lovastatin and measured Na(+)-K(+) pump current (I(p)) in isolated rabbit cardiac myocytes using the whole cell patch-clamp technique, K-dependent p-nitrophenyl phosphatase (p-NPPase) activity in crude myocardial and skeletal muscle homogenates, and vanadate-facilitated 3H-ouabain binding in intact skeletal muscle samples from rats.
  
  
  RESULTS
  Treatment with lovastatin caused statistically significant reductions in I(p), myocardial and skeletal muscle K-dependent p-NPPase activity and 3H-ouabain binding in the myocardium and skeletal muscle. The lovastatin-induced decrease in I(p) was eliminated by parenteral co-administration of mevalonate. However, this was not related to cardiac cholesterol content.
  
  
  CONCLUSIONS
  Treatment with lovastatin reduces Na(+)-K(+) pump activity and abundance in rabbit and rat sarcolemma.
authors.affiliation: Department of Cardiology, Royal North Shore Hospital, Sydney, Australia.
authors.forename: D F
authors.initials: DF
authors.lastname: Gray
authors.forename: H
authors.initials: H
authors.lastname: Bundgaard
authors.forename: P S
authors.initials: PS
authors.lastname: Hansen
authors.forename: K A
authors.initials: KA
authors.lastname: Buhagiar
authors.forename: A S
authors.initials: AS
authors.lastname: Mihailidou
authors.forename: W
authors.initials: W
authors.lastname: Jessup
authors.forename: K
authors.initials: K
authors.lastname: Kjeldsen
authors.forename: H H
authors.initials: HH
authors.lastname: Rasmussen
mesh_terms: D009597:4-Nitrophenylphosphatase / Q000378:metabolism; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D002784:Cholesterol / Q000008:administration & dosage / Q000097:blood; D005260:Female; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D050356:Lipid Metabolism; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D008798:Mevalonic Acid / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010042:Ouabain / Q000378:metabolism; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D012508:Sarcolemma / Q000187:drug effects / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010042:Ouabain; D002784:Cholesterol; D008148:Lovastatin; D012964:Sodium; D009597:4-Nitrophenylphosphatase; D000254:Sodium-Potassium-Exchanging ATPase; D011188:Potassium; D008798:Mevalonic Acid